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Abstract
Background: Patients with stroke are at a high risk for long-term handicap and disability. In the first weeks after
stroke muscle wasting is observed frequently. Early post-stroke rehabilitation programs are directed to improve
functional independence and physical performance. Supplementation with essential amino acids (EAAs) might
prevent muscle wasting and improve rehabilitation outcome by augmenting muscle mass and muscle strength. We
aim to examine this in a double blinded, randomized placebo-controlled clinical trial.
Methods: Patients with ischemic or haemorrhagic stroke will be enrolled at begin of the early post-stroke
rehabilitation in a parallel group interventional trial. Oral supplementation of EAAs or placebo will be given for
12 weeks in a double blinded manner. Physical and functional performance will be assessed by exercise testing
before supplementation of EAAs as well as at discharge from the in-patient rehabilitation, at 12 weeks and 1 year
afterwards.
Discussion: This is the first randomized double-blinded placebo-controlled clinical study aiming to assess the effect
of the EAAs supplementation on muscle strength, muscle function and physical performance in stroke patients
during early post-stroke rehabilitation. Supplementation of EAAs could prevent muscle mass wasting and improve
functional independence after stroke.
Trial registration: The study is registered at the German registry for clinical trials as well as at World Health
Organization (WHO; number DRKS00005577).
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Background
Long-term disability and functional dependency are
the main complications after stroke. Impaired skeletal
muscle innervation due to damage results in the de-
generation of motor units, paresis, and immobility
accompanied by skeletal muscle atrophy [1–4]. Not-
ably, loss of muscle mass and muscle function, de-
fined as sarcopenia, have been originally described as
a phenomenon of aging [5]. However, muscle wasting
observed in stroke patients is a disease-related
phenomenon and the term ‘stroke-related sarcopenia’
has been suggested [1]. The aetiology of sarcopenia is
multifactorial [6]. This is also true for stroke-depended
sarcopenia. Several pathophysiological mechanisms in-
cluding metabolic imbalance, inactivity, malnutrition, and
inflammation may contribute to the reduction of muscle
mass after stroke [7, 8]. Stroke-related muscle wasting is
accompanied by body weight loss, neuro-hormonal activa-
tion, and a systemic shift towards catabolic over-activation
[8]. In addition, activation of catabolic pathways in the
skeletal muscle of the paretic and non-paretic limbs has
been observed in experimental stroke [9].
Early rehabilitation has a great impact on the func-
tional recovery after stroke. A previous study showed
that 80 % of the patients achieve best functional recovery
within 6 weeks after stroke, and after 12.5 weeks 95 % of
all stroke patients completed their functional recovery
[10]. However, one year after stroke more than 30 % of
the patients remained functionally dependent [11].
Skeletal muscles play a central role in post-stroke re-
habilitation. The goal of rehabilitation is to restore func-
tional muscle capacity and to prevent long-term
disability. Therefore, prevention of muscle wasting, in-
creasing muscle strength, reactive development of novel
neuromuscular junctions, and stabilisation of the
catabolic-anabolic imbalance are primary aims of post-
stroke rehabilitation.
Nutritional intervention may contribute to the im-
provement of muscle bulk and functional capacity in
the early post-stroke rehabilitation. Thus, a beneficial
effect of dietary supplementation of essential amino
acids (EAAs) has been shown for an improvement of
skeletal muscle mass and function in the elderly [12,
13]. Availability of EAAs is regarded as a limiting step
in the synthesis of new muscle proteins [14].
Previously it has been shown that supplementation of
EAAs in the elderly was responsible for amino acid-
induced stimulation of muscle protein anabolism [15].
Therefore, an individually adjusted rehabilitation
program that includes physical, functional and neuro-
psychological training as well as dietary supplementa-
tion of the EAA might provide the best rehabilitation
outcome. Thus, in the present clinical trial the follow-
ing hypotheses will be tested:
 Oral uptake of EAAs restores skeletal muscle
function and physical performance;
 Oral uptake of EAAs contributes to physical
independence and enhances the effectiveness of
post-stroke rehabilitation;
 Availability of EAAs reduces muscle wasting after
stroke.
We aim to demonstrate that nutritional supplementa-
tion with biologically limited available EAAs (l-leucine,
l-lysine, l-isoleucine, l-valine, l-threonine, l-cystine, l-
histidin, l-phenylalanine, l-methionine, l-tyrosin, and l-
tryptophane), in synergy with individually adjusted phys-
ical training prevent muscle wasting after stroke and
improve the effect of post-stroke early rehabilitation.
Methods
Study design
The “Influence of essential amino acids on muscle
mass and muscle strength in patients with cerebral
stroke during early rehabilitation (AMINO-Stroke)”
study is a randomized double-blinded placebo con-
trolled interventional clinical trial. The study is
planed as a monocentric trial within the interdiscip-
linary trial programme of the Center for Stroke Re-
search Berlin (CSB) and is funded by the German
Federal Ministry of Education and Research (BMBF;
grant number CSB 01EO1301). The study has been
approved by the Brandenburg Ethics Committee for
the recruiting site (S13(a)/2013) and is conducted in
accordance with the Declaration of Helsinki. The
study is registered at the German registry for clinical
trials as well as at World Health Organization (WHO;
number DRKS00005577).
Patient eligibility
Patients admitted to the rehabilitation centre Branden-
burg Klinik, Bernau, Germany within 8 weeks after is-
chemic or haemorrhagic stroke will be screened for the
eligibility. Patients of both genders, aged 45 years or
older will be informed about the study. After obtaining
of written informed consent from the patients they will
be randomized 1:1 to intervention and control group by
a web-based online randomization procedure provided
by the Pharmacy at the Charité. For inclusion and exclu-
sion criteria see Table 1.
Planned clinical follow-up visits
In order to evaluate an effect of the EAAs on muscle
function, baseline functional assessment program will be
performed at admission, followed by follow-up assess-
ment at discharge from the in-patient rehabilitation
(Table 2). All patients included into the study will re-
ceive 12 weeks either the EAAs (4 gram, 3 times a day)
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or placebo dissolved in a glass of water as a drinking
solution.
Two weeks after the enrolment a study nurse visit for
evaluation of compliance of the EEAs supplementation
and tolerance to the compound is planned. After dis-
charge from the in-patient rehabilitation, two follow-up
visits at 3 and at 12 months are planned. Patients will be
tested for functional performance and physical inde-
pendence during a 1-day ambulatory visit. Patients, who
are unable to visit the study centre will be contacted by
telephone and interviewed using a standardised ques-
tionnaire. The study design is summarized in Fig. 1.
Outcomes and endpoints
Primary outcomes
Primary outcomes will be assessed at the 4 week follow-
up visit. Primary endpoints include:
1) Physical performance according to the Rivermead
motor assessment (RMA) gross function scale;




1) Functional outcome assessed by Barthel Index (BI);
2) Quality of life assessed according to EuroQoL (EQ)-
5D (EQ-5D) questionnaire at 3 and 12 months
follow up visits;
3) Muscle function and motor capabilities assessed by
pinch grip strength test, motor assessment scale,
Fugl-Meyer Score (motor functional domain), Func-
tional ambulatory capacity and short physical per-
formance battery test;
4) Changes of body composition assessed by
bioelectrical impedance analysis (BIA);
5) Changes in insulin sensitivity;
6) Changes of nutritional status according to Mini
Nutritional Assessment questionnaire and metabolic
profile according to biochemical analyses;
7) Rate of post-stroke complications, stroke –associated
infections and re-hospitalization for any reason;
8) Safety and tolerability of EEAs supplementation.
Physical examinations
Rivermead motor assessment (RMA) gross function scale
comprised a series of 13 questions, and covers a range of
activities from turning over in bed to hop on affected leg
five times [16, 17]. Hand grip strength [18] and pinch
grip tests measures muscle isometric strength. The max-
imum value of three measurements will be evaluated
[19]. Motor assessment scale (MAS) includes nine items
scoring from 0 to 6, and is designed to assess eight areas
Table 1 Inclusion and exclusion criteria of the AMINO-Stroke
Inclusion criteria:
• Patient >45 years
• Patients with ischemic or haemorrhagic stroke within 8 weeks to
enrolment
• Brain magnet resonance imaging or computer tomography
demonstrating stroke
• Motoric disability of an upper and /or lower limb (Rivermead Motor
Assessment Gross Function > 1 and <11)
• Signed informed consent
Exclusion criteria:
• Clinically significant findings on physical examination or presence of
clinically significant disease that would interfere with study evaluation
in the opinion of the treating physicians
• Participation in another clinical trial investigating a nutritional product
• History of intolerance or allergic response to similar nutritional
products or known hypersensitivity to essential amino acids
• Clinical sighs and symptoms of infection requiring antibiotic therapy at
the time of enrolment that prevent completion of trial-related assess-
ments as judged by the investigator
• Transaminases (AST or ALT) > 3 times the upper limit of normal (ULN)
• Severe renal dysfunction or nephrotic syndrome
• Acquired immunodeficiency syndrome, HIV or Hepatitis C infection
• Current therapy with anabolic steroids or appetite stimulants
• Current immunosuppressive therapy, heart transplantation, or renal
dialysis
• Life expectancy < 6 months
Table 2 Functional assessment at baseline and during
follow-up
Extended functional assessment at baseline and at 4 weeks follow-up
• Activity of daily living (modified Rankin scale, Barthel Index)
• Functional assessment scales and physical performance (Rivermead
Motor Assessment Gross Function, Fugl-Meyer Scale, Functional
ambulatory capacity)
• Muscle functional assessment (SPPBT, hand grip, pinch grip)
• Quality of life and nutritional status (EQ-5D, PGA)
• Blood and biomarker bank: metabolic /immunologic profile
• 24 h Holter electrocardiogram (ECG)
• Body composition by bioelectrical impendance analysis (BIA)
• Urine status
Functional assessment at 3 and 6 months follow-up
• Activity of daily living (mRS, Barthel index)
• Muscle functional assessment (SPPBT, hand grip, pinch grip)
• Quality of life and nutritional status (EQ-5D, PGA)
• Blood and biomarker bank: metabolic/immunologic profile
• 24 h Holter ECG
• Body composition by bioelectrical impedance analysis (BIA)
• Urine status
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of motor function, balance, and muscle tone [20]. Fugl-
Meyer scale is a system for the evaluation of motor func-
tion, balance, sensory qualities, and joint function in
hemiplegic patients. This system applies a cumulative
numerical score [21, 22]. Functional Ambulation Cat-
egory (FAC) includes six categories ranging from 0 to 5
and is defined by ability of the patient to ambulate, with
a lowest score 0 for “patient cannot ambulate” to 5 “pa-
tient can ambulate independently” [23].
Functional independency assessment
Barthel index (BI) will be used for the assessment of
functional independence. BI includes 10 basic aspects of
activities related to self-care and mobility with scores of
0–100, where the lower scores indicate greater depend-
ency [24]. Short physical performance battery test
(SPPBT) includes examination of ability to stand with
the feet together in the side-by-side, semi-tandem, and
tandem positions, time to walk 3 or 4 meters, and time
to rise from the chair and return to the seated position 5
times [25].
Nutritional status and quality of life
Mini Nutritional Assessment (MNA) is a simple scale to
measure nutritional status [26]. A score above 24 points
identifies patients with a good nutritional status, whereas
a score below 17 points reveals patients with malnutri-
tion. Subjective Global Assessment (SGA) assesses nutri-
tional status based on features of the history and
physical examination [27]. EQ-5D questionnaire is an in-
strument for the generic measurements of health-related
quality of life, comprising a Visual Analogue Scale for
self-rating of general health and five domains evaluating
mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression [28]. A score of 1 is the best possible
general health status in each case; the dimensions may
also be expressed as percentage of patients scoring from
1 to 3 (best to worst health status) or percentage of pa-
tients with ‘any’ complaint (scoring 2 or 3 in each do-
main) [29].
Body composition analysis
Body composition analysis at baseline and follow-up
visits will be assessed by BIA device (BodyStat QuadScan
4000, Bodystat Limited, British Isles). The BIA device
measures resistance (R), reactance (Xc) and phase angle
(φ). The measurements will be performed in patients in
supine position lying on a non-conducting surface with
arms slightly abducted from the trunk and legs slightly
separated, after resting at least for 20 min [30]. Surface
electrodes will be placed on the dorsal surface of hand
and foot of the similar side. Skeletal muscle (SM) mass
will be estimated according to the equation of Baumgart-
ner at all [31].
Serum biomarker assessment
Blood samples and urine status will be assessed at ad-
mission and discharge from the inpatient rehabilitation
as well as at follow up visits for routine clinical parame-
ters, inflammatory and metabolic markers, and safety
analyses (liver and kidney function).
Fig. 1 Overview of the AMINO-Stroke study
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Sample size calculation and statistical analyses
A total of 110 patients is planned to be enrolled in the
study. A prospective sample size calculation has been per-
formed based on observational data from our study
centre. A sample size of 55 in each group will have 80 %
power to detect a clinically relevant difference in River-
mead Motor Assessment Gross Function scale improve-
ment between the groups of 1.5 points and a clinically
relevant improvement of handgrip strength. The analysis
of primary endpoints will use the principle of intention-
to-treat. The carry-forward principle will be adopted for
unavailable or missing data. Treatment effect will be
assessed by unpaired comparison of both treatment arms
for the change from baseline using the Student t-test. A
significance level of α < 0.05 will be specified to indicate
statistical significance. Secondary endpoints will be ana-
lyzed using standard statistical methods. For safety end-
points Chi-squared test of Fisher’s Exact test will be used
for event rates (e.g., death, re-stroke, hospitalization, car-
diovascular event)
Discussion
The present AMINO Stroke study will be the first ran-
domized double-blinded trial investigating an effect of
essential amino acids (EAAs) on skeletal muscle func-
tional capacity, muscle mass, muscle strength and phys-
ical performance in early post-stroke rehabilitation. In
addition, the effect of EAAs supplementation on stroke-
related quality of life, nutritional status, activities of daily
life and outcome will be evaluated.
An improvement of physical and functional perform-
ance in stroke patients is expected after participating in
4-weeks rehabilitation program [32]. In the present
study we expect a beneficial impact of the dietary sup-
plementation of the EAA on skeletal muscle function
and muscle mass during post-stroke rehabilitation.
The benefit of EAAs supplementation on skeletal
muscle has been shown in several studies in elderly indi-
viduals. Thus, an elevated level of muscle protein syn-
thesis was dependent on the availability of EAAs in a
dose-depended manner [33]. An experimental study per-
forming in the young adults revealed an increase of leu-
cine incorporation into the skeletal muscle proteins
under administration of EEAs as a flooding dose [34].
Ingestion of EAAs shortly after exercise enhanced
muscle protein synthesis in older adults, indicating a
combination of EAAs with exercising as a sufficient
therapy for the treatment of muscle wasting [35]. An-
other study showed an improvement of lean mass,
muscle functional capacity and muscle strength after
16 weeks supplementation of EAAs and arginine in
healthy elderly individuals [36].
A reduction of the muscle mass might be directly de-
pending on a limited availability of the EEAs and other
nutrients [14]. Impaired feeding which results in malnu-
trition is frequently observed in patients with dysphagia
after stroke [37]. About 50 % of stroke patients have
feeding difficulties due to dysphagia [38]. In older pa-
tients reduced nutritional status might be observed
already at hospital admission with the diagnosis of acute
stroke [39]. Patients with lower body weight have been
observed to have worse fatal and non-fatal outcome after
stroke [40]. While the inverse association of overweight
and improved outcome has previously been termed
obesity paradox [41], the perception advanced towards
an obesity paradigm, acknowledging the protective over-
weight in cardiovascular disease [42].
Malnutrition and sarcopenia are often reported in the
rehabilitation setting [43, 44]. Therefore, we believe that
supplementation of the EAAs will contribute to attenu-
ation of muscle wasting and improve skeletal muscle re-
covery [45]. There are a number of methods available to
assess muscle mass [46]. In the present study muscle
mass will be estimated by using BIA that provides infor-
mation to integrity of cell membrane and tissue inter-
faces, intracellular and extracellular fluid distribution,
body fat and body lean mass [31, 47]. Previously, a
strong correlation between muscle mass assessed by BIA
and magnetic resonance imaging has been shown [48].
The prevalence of sarcopenia using BIA measurements
has been repeatedly examined in elderly [49, 50], and in
patients with neuromuscular or cerebrovascular disease
[51, 52]. Therefore we believe that BIA is an appropriate
method for muscle mass assessment.
In Germany, stroke has not been selected for chronic
disease management programs so far [53]. Post-stroke
rehabilitation is usually recommended to start immedi-
ately following hospital discharge. The so called early
post-stroke rehabilitation phase includes about 4 weeks.
Mainly, recommendations given in discharge letters
from acute care hospitals are frequently focusing on
medical treatments [53]. At present, post-stroke man-
agement does not include monitoring of muscle mass,
muscle strength and muscle function. The European
stroke guidelines do not consider post-stroke muscle
wasting as a relevant complication [54]. However, recog-
nition of this problem through the medical community
might improve the long-term outcome after stroke.
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